TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Symptom scores of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom scores of throat pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom scores of vocal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staheli's arch index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Navicular height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiographic indexes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recognition of positive and negative facial expressions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants with categorical scores on the C-SSRS
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of detecting small liver tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of positive margins of resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quantitative Sensory Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Daily Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 Hour Dopamine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in BOLD signalling in the NAcc during effort allocation task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Trial-to-trial variability in reward seeking in an effort allocation task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in BOLD signalling in the NAcc for food-cue reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wound closure results of skin wounds after healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Subject's assessment of pain with application of microMend
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of solicited local and general symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: diastolic arterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perineal trauma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Time Spent With CGM Glucose < 54 mg/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Limb Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Limb Pistoning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Drinking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corrected Distance Monocular Visual Measurement Reported as Visual Acuity (VA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Operative Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Humoral immunogenicity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hospitalisation for infection
Endpoint domain: Adverse events/effects
Primary endpoint: endothelial-dependent microvascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion swab negative at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Ordinal Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment-emergent and treatment related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative thrombembolism
Endpoint domain: Adverse events/effects
Primary endpoint: Ability of palliative capecitabine and gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopment and behavioral health assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: safety profile (adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Ventilator Associated Pneumonia (VAP)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in carotid vessel wall volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Time to the First Occurrence of a Ventricular Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intrusive memories
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Walking Economy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between WR and FEV1 measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Correlation between clinical parameter and WZ measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucositis Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mouth Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Related Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Presence of external root resorption (ERR) in mandibular 2nd molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Proportion of patients achieving viral suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Objective change in gait kinematics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective change in gait
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of thorax electrical impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain post-tonsillectomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum thromboxane B2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Progression Free Survival (PFS) after 1 Year Treatment
Endpoint domain: Mortality/survival
Primary endpoint: Activity limiting flare-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sleep Apnea Prediction
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Injection Site Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yield of EM Tip-tracked Devices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in substance use frequency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of Atrial Fibrillation (AF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Size of the subacromial space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of subjects achieving 50% or more repigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cumulative Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Functional Independence Measure
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Distance between the pleura and the line of the imaginary needle pathway (DPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with resolution on day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Working Memory Capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Knee Injury and Osteoarthritis Outcome Score (KOOS4)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mindfulness level as measured by the Five Facet Mindfulness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Albuminuria-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of initial Edinburgh Postnatal Depression Scale (EPDS) score by 50% or more
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of EPDS score to less than or equal to 9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CGI change score achievement of very much improved or much improved
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of vaccine-associated serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects that seroconvert (greater than or equal to 4-fold rise in antibody titer)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of Grade 3 or 4 laboratory values
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects that develop a positive take response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain Tolerance - CPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Tolerance - PPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Tolerance - TPPT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the C3-Cloud system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usefulness of the C3-Cloud system
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: P/F ratio at day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain and Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of severe asthma exacerbations per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cerebral tissue oxygen saturation (crSO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-tf of BIBR 953 ZW
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum angiotensinogen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in sex-hormone binding globulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of subjects achieving at least a 30% decrease in iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean change in MSHQ ejaculation total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: HS Physician Local Improvement assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biologic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Line Breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Line Replacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Line Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Psychological Distress score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Understanding degree
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: long-term disease control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quantitative Sensory Testing (QST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in National Early Warning Score (NEWS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 7-point Ordinal Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to a Negative COVID-19 Nucleic Acid Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of hepatitis A antibody concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurobehavioral development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Recurrent rate of advanced endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Need for NICU admission and/or oxygen therapy or PPV for >30 minutes
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sustained virologic response (SVR) rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response (partial and complete)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of medical management for early pregnancy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mucociliary Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the concentration time curve from zero to infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of drug in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in Total Clinical Score (TCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patterns of Constitution in Chinese Medicine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patterns of Body Constitutions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Brief Rating of Aggression by Children and Adolescent (BRACHA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN1+)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Persistent Infection Associated With HPV-16 and/or HPV-18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: COVID-19 incident cases
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence rate of type II endoleaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean Change in Hb Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in SGRQ-C score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Counter stigma of cervical cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Late Lumen Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Clinically Significant, Non-hematologic Grade 3 or 4 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Cytotoxic T-lymphocyte effector frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delivery prior to 37 weeks' gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Temporal Summation of Pain (TSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1C levels (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inflammatory blood status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone regeneration volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of spontaneous preterm birth
Endpoint domain: Mortality/survival
Primary endpoint: Change in hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: In-segment late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Microbiome outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of change in GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in serum creatinine to 1.5 times the baseline value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: No serious medical complication due to infection
Endpoint domain: Adverse events/effects
Primary endpoint: Response without rehospitalization or changing randomized antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients with abnormal MRI-derived tissue signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of local disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Time to treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to consultation with other specialties
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Distribution ratio of total radioactivity in whole blood and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total radioactivity in excreta after oral [14C] ICP-022
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Function, short form 10a (SF10a)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percent change in in-stent stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in Percent Body Fat (%BF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Difference in Glucose Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Distance Binocular Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Near Binocular Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse event monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of obesity, cachexia and type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of a new MS-based biomarker for diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Primary Lesion Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Adverse Events (MAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: serum β-HCG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing attachment level gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone level gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Serious Adverse Event (SAE) and Non-serious Adverse Event (Non-SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Adverse Event Leading to Withdrawal (AELD) From the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of acquired resistance mechanisms to osimertinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of covered surface
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in estimated Blood Alcohol Concentration (eBAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicular fluid androstenedione levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: RT-PCR results for aromatase in follicular fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Oral opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major pathologic response (MPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Significant tumor necrosis (STN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes